Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the shares. The firm notes Q2 update represented another strong showing for Filspari with Travere reporting a Filspari beat. With PSFs continuing to show growth, Wedbush thinks this bodes well for the forward revenue trajectory.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Reports Strong Q2 2025 Growth
- Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics
- Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
- Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion
- Buy Rating on Travere Therapeutics: Undervaluation Amidst IgAN and FSGS Opportunities